ERBB2 and breast cancer: When the surrogate molecular classification was considered, the percentage of HER2 positive BC was significantly higher in PABC patients (10%) compared with nulliparous young women (1%) or in the >2 years since the last pregnancy group (2.2%) (p = 0.01).